无溶剂大豆浓缩蛋白的生产工艺

采用物理压榨法制取大豆粉,以此大豆粉为原料,通过酸法改性制取大豆浓缩蛋白,旨在获得无溶剂残留的大豆浓缩蛋白。制得大豆浓缩蛋白的蛋白质含量≥65%、NSI≥70%、脂肪≤1.0%、保油性明显提高。     

Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States

Background: Inhibitor development to factor VIII (FVIII) hemophilia therapy results in increased complications and substantial economic costs. The SIPPET study, the first randomized controlled trial to compare the immunogenicity of plasma-derived FVIII (pdFVIII)/von Willebrand factor (VWF) and recombinant-DNA-derived FVIII (rFVIII), demonstrated higher inhibitor rates in previously untreated patients (PUPs) treated with rFVIII than in PUPs treated with pdFVIII/VWF.

Objective: To quantify the economic impact of treating PUPs with pdFVIII/VWF vs rFVIII.

Methods: An Excel-based clinical and economic model was developed from a US healthcare payer perspective and run over a 5-year period. The analysis utilized a cohort approach to model patient treatment and outcomes over a monthly cycle to quantify differences in costs of FVIII, bypassing agents, and hospitalizations for serious bleeds. Rates of high-titer inhibitor development were obtained from the SIPPET study. Patients developing high-titer inhibitors were treated with immune tolerance induction (ITI). Patients who developed low-titer inhibitors and those who did not develop inhibitors continued their usual FVIII treatment. Patients who were successfully treated with ITI returned to FVIII treatment, while unsuccessfully treated patients received bypassing agents. Total costs per treated patient were estimated and a one-way sensitivity analysis was conducted to quantify the impact of parameter uncertainty on the model outcomes.

Results: Total cumulative costs per patient over 5 years were $834,621 for pdFVIII/VWF patients and $1,237,163 for rFVIII patients, representing a total saving of $402,542 per patient over the 5-year period, for an average annual saving of $80,508 per patient.

Conclusions: Based on data from the SIPPET study, this analysis found that initiating FVIII treatment in severe hemophilia A PUPs with pdFVIII/VWF has the potential to offer substantial cost savings to healthcare payers, amounting to a one-third reduction in costs.     

蛋白质溶胶的流变特性及应用研究进展

介绍了蛋白质和改性蛋白质溶胶的流变特性，指出蛋白质溶胶的流变特性主要为非牛顿流体的假塑性流体，且其流变特性受诸多因素的影响；蛋白质经过改性后，流动性有较大的改善。最后概述了蛋白质溶胶流变特性方面的应用。     

运动个体如何科学摄入蛋白质

蛋白质是组成人体结构成分和酶等特殊的功能性物质,并在生命过程中发挥着关键性作用。它是人体的主要成份之一,也是人体内部进行各种代谢活动的物质基础。蛋白质在机体内的存在形式和作用是多样化的,与运动个体的肌肉力量和肌肉蛋白合成紧密相关。在运动过程中,骨骼肌收缩活动会影响蛋白质和氨基酸代谢,这种运动的影响还延续到运动后。     

KDN型定氮仪测定粮食中粗蛋白质含量的相关问题探讨

目前测定蛋白质的方法和仪器很多,为了提高蛋白质含量检测结果的准确性和检测效率,依据GB/T 5511-2008《谷物和豆类氮含量测定和粗蛋白质含量计算凯氏法》要求,常用定氮仪来测定粮食中粗蛋白质含量。对此方法中化学试剂硫酸的选择及实际操作进行了探讨。     

TGF-β及其受体对胚胎着床的影响

TGF—β（transforming growth factor—β，TGF—β）是一类在结构上相对保守的生长因子，是细胞增殖、分化、细胞外基质合成和细胞凋亡的主要调节因子之一。近年来也发现，该家族成员的部分因子如TGF—β、骨形态形成蛋白（bone morphogeneticp rotein，BMP）／生长分化因子（growth and differentiation factor，GDF）、激活素／抑制素（Activin／Inhibin）也参与胚胎着床过程，且这些生长因子的表达表现出时空特异性。     

水生观赏动物活饵料应用技术展望

在水生观赏动物的人工育苗中，幼体阶段的活饵料是育苗成功的关键之一。本文着重探讨了轮虫（如褶皱臂尾轮虫）、卤虫、桡足类（如日本虎斑猛水蚤、哲水蚤等）、枝角类（如蒙古裸腹涵和西藏拟泾）等饵料浮游动物的营养特点、培养利用现状及其在水生观赏动物养殖中的应用前景。为水生观赏动物养殖中活饵料使用和开发新的饲料蛋白源提供参考。     

动物对温度适应的分子生物学研究进展

动物对环境温度的适应,会使自身的细胞内转录和表达模式发成变化,以适合环境的变化,此时它会出现新的基因开放和新蛋白因子的合成,这总的来说是动物对自身的一种保护方式。本文从基因水平、蛋白质水平、细胞膜水平等三个方面综述了动物对环境温度适应的研究概况,并讨论了动物对环境温度适应的分子生物学机制以及在进化中的意义。     

大豆蛋白非食品应用研究

大豆蛋白是大豆的主要农产品之一,主要在材料粘合剂、生物降解膜和塑料材料、纤维材料和生物医用材料等几个领域研究较多。随着目前全球性环境问题和石油资源的日益紧张,天然高分子材料的开发成为21世纪科学工作者研究的热点课题。文章就大豆蛋白在非食品方面的应用展开叙述,总结了大豆蛋白在胶粘剂、大豆蛋白膜、大豆蛋白塑料、大豆蛋白纤维和生物医用材料方面的应用。